Information Provided By:
Fly News Breaks for December 6, 2019
Dec 6, 2019 | 07:07 EDT
H.C. Wainwright analyst Edward White initiated coverage of Puma Biotechnology with a Buy rating and $15 price target. The analyst believes metastatic breast cancer is a "sizeable opportunity" for the company to capitalize on with Nerlynx. He sees a "promising future" for the drug.
News For PBYI From the Last 2 Days
There are no results for your query PBYI